Lexeo Therapeutics (NASDAQ:LXEO) CFO Sells $20,214.47 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CFO Louis Edward Tamayo sold 4,117 shares of Lexeo Therapeutics stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $4.91, for a total transaction of $20,214.47. Following the completion of the transaction, the chief financial officer directly owned 92,907 shares in the company, valued at approximately $456,173.37. The trade was a 4.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Louis Edward Tamayo also recently made the following trade(s):

• On Wednesday, July 1st, Louis Edward Tamayo sold 4,641 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $4.49, for a total transaction of $20,838.09.

Lexeo Therapeutics Stock Down 3.6%

NASDAQ:LXEO opened at $4.88 on Friday. The firm has a market capitalization of $400.40 million, a P/E ratio of -4.24 and a beta of 1.46. The company has a fifty day moving average of $4.73 and a 200 day moving average of $5.54. Lexeo Therapeutics, Inc. has a 52 week low of $3.99 and a 52 week high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). As a group, analysts anticipate that Lexeo Therapeutics, Inc. will post -1.18 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in LXEO. BlackRock Inc. bought a new stake in shares of Lexeo Therapeutics during the 2nd quarter valued at about $26,717,000. Montanova Capital LLC increased its position in shares of Lexeo Therapeutics by 410.7% during the second quarter. Montanova Capital LLC now owns 6,384,200 shares of the company’s stock valued at $29,718,000 after buying an additional 5,134,200 shares during the period. RA Capital Management L.P. bought a new position in Lexeo Therapeutics in the fourth quarter worth about $49,650,000. Paradigm Biocapital Advisors LP bought a new position in Lexeo Therapeutics in the fourth quarter worth about $47,299,000. Finally, Balyasny Asset Management L.P. bought a new position in Lexeo Therapeutics in the second quarter worth about $16,117,000. 60.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. reduced their price target on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, June 25th. Weiss Ratings raised Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Wall Street Zen cut Lexeo Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, August 15th. Finally, Chardan Capital upgraded Lexeo Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $18.75.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.